Yazar "Celik, Aykut Ferhat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology - Gastroenterology Collaborative Initiative
    (Wiley, 2019) Hatemi, Gulen; Akar, Servet; Akpinar, Hale; Atagunduz, Pamir; Bengi, Goksel; Can, Gercek; Celik, Aykut Ferhat
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Frequency of gallstones after renal transplantation and factors that affect gallstone formation
    (John Wiley & Sons Inc, 2007) Celik, Aykut Ferhat; Altiparmak, Mehmet Riza; Pamuk, Guelsuem Emel; Pamuk, Oemer Nuri; Apaydin, Sueheyla
    BACKGROUND: We investigated the frequency of gallstones (GSs) in our renal transplant recipients and evaluated the effects of various factors on GS formation. METHODS: One hundred and eight-two patients who had undergone renal transplantation at our center in the last 12 years were included in the study. Of these, 163 patients were followed up regularly, of whom 118 were using cyclosporine A (CsA). Abdominal ultrasonography of all patients was performed, and biochemical parameters were also determined. RESULTS: Median duration of patient follow-up was 36 months. GSs were diagnosed in 5 patients (3.1%). Mean age and follow-up duration of the CsA group were lower than those of the non-CsA group (p < 0.05 and p < 0.001, respectively). The frequency of GSs was 3.4% in the CsA group and 2.2% in the non-CsA group (p > 0.05). Median time to detect GS formation in the post-transplantation period was 85 months. The CsA group had a significantly shorter GS-free follow-up period than the non-CsA group (p = 0.008). According to Cox multivariate regression analysis, the only factor that affected GS formation in the post-transplantation period was the use of CsA. CONCLUSION: The use of CsA showed a trend toward increasing the risk of developing a GS sooner in the post-transplant period, particularly for young men.
  • Küçük Resim Yok
    Öğe
    Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic
    (Aves, 2021) Toruner, Murat; Kalkan, Ismail Hakki; Akyuz, Filiz; Tezel, Ahmet; Celik, Aykut Ferhat
    The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.